Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

403.21 +2.34 (+0.58%)
Streaming Delayed Price Updated: 3:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutic

< Previous 1 2 3 4 5 6 7 8 9 Next >
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Krystal Biotech Stock Sees RS Rating Jump To 91
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. 
Via Investor's Business Daily
For those who appreciate value investing, NASDAQ:UTHR is a compelling option with its solid fundamentals.
Investors should take notice ofUNITED THERAPEUTICS CORP (NASDAQ:UTHR)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Expert Ratings For United Therapeutics
Via Benzinga
The Latest Analyst Ratings For United Therapeutics
Via Benzinga
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks. 
Via InvestorPlace
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Liquidia stock retook its 50-day line Monday on a U.S. judge's ruling on a patent dispute with fellow biotech company United Therapeutics. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals. 
Via Chartmill
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyvaso leads the charge with a 56% revenue surge. 
Via Benzinga
UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024
UTHR stock results show that United Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
From United Therapeutics Corporation
Via Business Wire
NASDAQ:UTHR stands out as a stock that provides good value for the fundamentals it showcases.
Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued. 
Via Chartmill
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
From United Therapeutics Corporation
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
From United Therapeutics Corporation
Via Business Wire
The Bargain Hunter’s Portfolio: 7 Smart Stock Buys for the Shrewd Investor
Although several companies have seen their valuations blossom, you can still find bargain stocks if you know where to look. 
Via InvestorPlace
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024
Learn about these undervalued NASDAQ stocks teeming with the potential to bounce back and show great returns for investors this year. 
Via InvestorPlace
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward. 
Via InvestorPlace
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.